Glacier Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.90 M
- Company Age 25 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.90 Cr
- Revenue Growth -9.08%
- Profit Growth -13.91%
- Ebitda -20.65%
- Net Worth 1059.78%
- Total Assets 7.36%
About Glacier Pharmaceuticals
Glacier Pharmaceuticals Private Limited (GPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 04 November 1999 and has a history of 25 years and three months. Its registered office is in Amravati, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.90 M.
The company currently has active open charges totaling ₹1.90 Cr.
Ashok Nanwani and Varsha Nanwani serve as directors at the Company.
Company Details
-
Location
Amravati, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230MH1999PTC122545
-
Company No.
122545
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Nov 1999
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Glacier Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashok Nanwani
|
Director | 01-Jan-2003 | Current |
|
Varsha Nanwani
|
Director | 06-Jan-2017 | Current |
Financial Performance of Glacier Pharmaceuticals.
Glacier Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.08% decrease. The company also saw a substantial fall in profitability, with a 13.91% decrease in profit. The company's net worth Soared by an impressive increase of 1059.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glacier Pharmaceuticals?
In 2023, Glacier Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹19.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 1.50 Cr
- The Akola Urban Co-Op. Bank Ltd. : 0.40 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Dec 2017 | Others | ₹1.50 Cr | Open |
| 13 Mar 2007 | The Akola Urban Co-Op. Bank Ltd. | ₹4.00 M | Open |
How Many Employees Work at Glacier Pharmaceuticals?
Unlock and access historical data on people associated with Glacier Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glacier Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glacier Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
